Blog

Pharmacokinetic / dissolution claims save sustained release combination of naltrexone and bupropion from generic challenge.

Federal Circuit reversed district court decision to dismiss patent lawsuit at pleadings stage because dose adjustment required by claims was concrete application of natural law.

FDA clarifies requirements to be listed as the active ingredient in a drug product.

When will a preamble to a claimed method of treatment be given limiting effect? The answer might surprise you.

American patent rules seem to foreclose additional patent protection for new stereoisomers, while European patent rules offer some margin of hope.

Federal Circuit rules that eligibility for drug / diagnostic patent turns on distinction between manipulative steps and mental steps.

Patent claiming dose reduction for poor metabolizers affirmed at Federal Circuit.

Capital gains treatment is available only if the royalties are paid as consideration for all substantial rights to a patent.

Rejection of methyl homolog as prima facie obvious over old compound reversed under lead compound analysis.

Japanese patent laws allow applicants to extend patent protection an additional 18 months by following a simple filing sequence.